Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease

Autor(es)

Orestes V. Forlenza ^[1] ; Breno S. Diniz ^{[1, 2]} ; Antonio L. Teixeira ^{[3, 4]} ; Florindo Stella ^{[1, 5]} ; Wagner Gattaz ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Med, Dept & Inst Psychiat, Lab Neurosci LIM 27, BR-05403010 Sao Paulo - Brazil

^[2] Univ Fed Minas Gerais, Sch Med, Dept Mental Hlth, Belo Horizonte, MG - Brazil

^[3] Univ Fed Minas Gerais, Inst Biol Sci, Lab Immunopharmacol, Neuroimmunol Grp, Belo Horizonte, MG - Brazil

^[4] Univ Fed Minas Gerais, Sch Med, Dept Internal Med, Belo Horizonte, MG - Brazil

^[5] Univ Estadual Paulista, Biosci Inst, Rio Claro, SP - Argentina

• Tipo de documento: Artigo Científico
• Fonte: Revista Brasileira de Psiquiatria; v. 35, n. 3, p. 284-294, 2013-09-00.

Resumo

Objective: To present a critical review of publications reporting on the rationale and clinical implications of the use of biomarkers for the early diagnosis of Alzheimer's disease (AD). Methods: We conducted a systematic search of the PubMed and Web of Science electronic databases, limited to articles published in English between 1999 and 2012, and based on the following terms: mild cognitive impairment, Alzheimer's disease OR dementia, biomarkers. We retrieved 1,130 articles, of which 175 were reviews. Overall, 955 original articles were eligible. Results: The following points were considered relevant for the present review: a) rationale for biomarkers research in AD and mild cognitive impairment (MCI); b) usefulness of distinct biomarkers for the diagnosis and prediction of AD; c) the role of multimodality biomarkers for the diagnosis and prediction of AD; d) the role of biomarkers in clinical trials of patients with AD and MCI; and e) current limitations to the widespread use of biomarkers in research and clinical settings. Conclusion: Different biomarkers are useful for the early diagnosis and prediction of AD in at-risk subjects. Nonetheless, important methodological limitations need to be overcome for widespread use of biomarkers in research and clinical settings. (AU)

• Processo FAPESP: 09/52825-8 - Neurobiologia da doença de Alzheimer: marcadores de risco, prognóstico e resposta terapêutica
• Beneficiário: Wagner Farid Gattaz
• Modalidade de apoio: Auxílio à Pesquisa - Temático